Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy
ConclusionsHR-positive young breast cancer patients have a poorer survival compared with older patients, even with more frequent chemotherapy, but more recent use of tamoxifen and ovarian suppression might improve this outcome in these patients.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Endocrine Therapy | HER2 | Hormonal Therapy | Hormones | Ovarian Cancer | Ovaries | Tamoxifen | Women